In Fortress Iron v. Digger Specialties, the Federal Circuit held that when a co-inventor cannot be located and added under § 256(b), the patent is invalid.
In Hikma v. Amarin, SCOTUS will decide whether generic drug marketing statements can support induced infringement claims even when the FDA label carves out the patented use — with major implications f
In REGENXBIO v. Sarepta Therapeutics, the Federal Circuit reversed a district court and held that recombinant host cells are patent eligible — setting new precedent for gene therapy, CAR-T, and mRNA I
In Seagen v. Daiichi Sankyo, the Federal Circuit reversed a damages verdict and held broad antibody‑drug conjugate claims invalid for inadequate written description & enablement under §112(a).
